Yu Shen

Director & Research Fellow, Oncology Discovery

Dr. Shen is a leader of oncology drug discovery with more than 20 years of industry experience. He joined Abbott Laboratories/Abbvie in 2001 and became a member of Abbott’s prestigious Volwiler society in 2010. Dr. Shen had assumed increasing responsibilities during his tenure at Abbott/AbbVie, and led the advancement of multiple drug discovery programs through stages ranging from target identification/validation, HTS, lead generation, lead optimization, clinical candidate selection, translational biomarker studies, up to IND filing and translational support of assets in clinical trials. Dr. Shen has a deep understanding of drug discovery and oncology translational studies, broad knowledge on multiple areas of cancer biology such as immuno-oncology, epigenetics, signal transduction, cell cycle regulation, apoptosis, tumor microenvironment, and extensive experiences on diverse therapeutic modalities, including small molecules, antibody drug conjugates, nucleic acids, and more recently PROTACs. Prior to joining Abbott, Dr. Shen received his BS and MS degrees from Nanjing University in China, and earned his doctorate in cell biology at the University of North Carolina at Chapel Hill.

Talks About
#drugdiscovery #drugdesign #pharmacology

Preferred Locations
#UnitedStates